Каламушларда гипертиреоз ёки гипотиреозни келтириб чиқариш учун ҳар куни меъда ичак тракти орқали L-тироксин (200 мкг/сутка 1 кг тана вазнига) ёки мерказолил (10 мг/сутка 1 кг тана вазнига) 14 ва 21 кун давомида берилди. Ҳайвонларга L-тироксин юборгандан сўнг қон зардобида тироксин миқдори 83 ва 136% га ошди, тиреотропгармон (ТТГ) миқдори эса камайди (56 ва 76%). Мерказолил юборилган каламушлар қон зардобида эркин тироксин миқдори 38 ва 62 % га камайди ва ТТГ миқдори 59 ва 550% га ошди, бунда эркин трийодтиронин миқдори 66 ва 74% га камайди. Экспериментал гипотиреоз қонда цистеин миқдорининг ошиши билан кечди (14 кунда 24% га ва 21 кунда 39% га). Мерказолил қўллагандан сўнг гомоцистеин миқдори ошди (98 ва 160%) ва гидроген сульфид миқдори камайди (17 ва 24%). Шундай қилиб, олтингугурт сақловчи аминокислоталар алмашинувининг бузилиши гипотиреоз билан оғриган беморларда кардиоваскуляр асоратлар ривожланишида маълум патогенетик роль уйнаши мумкин.
For hyperthyroidism and hypothyroidism modeling L-thyroxin (200 g/day per 1 kg of body weight) or merkazolil (10 mg/day per 1 kg of body weight) were administered to rats intraperitoneally daily for 14 and 21 days. Administration of L-thyroxin resulted in the increase of serum free thyroxin concentration by 83 and 136%, at the same time the thyroid-stimulating hormone level was significantly decreased (by 56 and 76%). Merkazolil caused the decrease of serum free thyroxine level by 38 and 62% and increase of thyroidstimulating hormone by 59 and 550%, while the level of free triiodothyronine was decreased by 66 and 74%. Experimental hypothyroidism was accompanied with the increase of cysteine level in blood (by 24% on 14th day and 39% on 21-st day). Merkazolil resulted also in the increase of homocysteine concentration (by 98 and 160%) and decrease of hydrogen sulphide level (by 17 and 24%). It has been concluded that disorders of sulfur amino acids metabolism could play a pathogenic role in the development of cardiovascular complications in patients with hypothyroidism.
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Nechiporuk V.M. | ||
| 2 | Korda M.M. |
| № | Ҳавола номи |
|---|---|
| 1 | 1. Определение содержания гидроген сульфида в сыворотке крови / В. Заичко, Н. А. Пентюк, Л. А. Пентюк, А. В. Мельник // Вестник научных исследований. – 2009. – № 1. – С. 29–32. 2. Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms / J. Zhou, R. C. Austin. // Biofactors. – 2009. – Vol. 35, № 2. – P. 120–129. 3. Dombkowski R. A. Hydrogen sulfide as an endogenous regulator of vascular smooth muscle tone in trout / R. A. Dombkowski, M. J. Russell, К. R. Olson // Am. J. Physiol. Regul. Integr. Comp. Physiol. – 2004. – Vol. 286, № 4. – P. 678–685. 4. Effects of thyroxine on L-cysteine desulfuration in mouse liver / M. Wróbel, T. Ubuka, W. B. Yao [et al.] // Acta Med Okayama. – 2000. – Vol. 54, № 1. – P. 9–14. 5. Folic acid alleviates oxidative stress and hyperhomocysteinemia involved in testicular dysfunction of hypothyroid rats / W. Ibrahim, E. Tousson, E. M. Ali [et al.] // Gen Comp Endocrinol. – 2011. – Vol. 174, № 2. – P. 143–149. 6. Gaitonde M. K. A spectrophotometric method for the direct determination of сysteine in the presence of other naturally occurring аmino acids / M. K. Gaitonde // Biochem. J. – 1967. – Vol. 104, № 2. – Р. 627–633. 7. Homocysteine, folate, and cobalamin levels in hyperthyroid women before and after treatment / A. Orzechowska-Pawilojc, M. Siekierska-Hellmann, A. Syrenicz [et al.] // Endokrynol Pol. – 2009. – Vol. 60, № 6. – P. 443–448. 8. Hydrogen sulfide and vascular relaxation / Y. Sun, C. S. Tang, J. B. DU [et al.] Chin Med J (Engl). – 2011. – Vol. 124, №22. – P.3816-3819. 9. Interactions of multiple gas-transducing systems: hallmarks and uncertainties of CO, NO, and H2S gas biology / M. Kajimura, R. Fukuda, R. M. Bateman [et al.] // Antioxid Redox Signal. 2010 – Vol. 13, № 2. – P. – P. 157–192. 10. Nutritional and functional importance of intestinal sulfur amino acid metabolism / A. K. Shoveller, B. Stoll, R. O. Ball [et al.] // J. Nutr. – 2005. – Vol. 135, №7. – P.1609–1612. 11. Plasma homocysteine levels in hyperthyroid patients / B. Demirbas, M. Ozkaya, E. Cakal [et al.] // Endocr J. – 2004. – Vol. 51, № 1. – Р. 121-125. 12. Role of hydrogen sulfide in secondary neuronal injury / J. F. Wang, Y. Li, J. N. Song [et al.] // Neurochem. Int. – 2014. – Vol. 64. – P. 37–47. 13. Sulfur containing amino acids and human disease / D.M. Townsend, K. D. Tew, H. Tapiero // Biomed. Pharmacother. – 2004 – Vol. 58, №1. – P. 47–55. 14. The role of endogenous H2S in cardiovascular physiology / N. Skovgaard, A. Gouliaev, M. Aalling [et al.] // Curr. Pharm. Biotechnol. – 2011. – Vol. 12, № 9. –P. 1385–1393. 15. Y. K. Gupta Gaso-transmitter hydrogen sulphide: potential new target in pharmacotherapy // Y. K. Gupta, A. K. Dahiya, K. H. Reeta // Indian J Exp Biol. 2010 – Vol. 48, № 11. – P.1069–1077. |